Wegovy(r) receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

MLA

“Wegovy(r) Receives FDA Approval for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity.” Plus Company Updates, 11 Mar. 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.787023005&authtype=sso&custid=ns315887.

APA

Wegovy(r) receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. (2024, March 11). Plus Company Updates.

Chicago

Plus Company Updates. 2024. “Wegovy(r) Receives FDA Approval for Cardiovascular Risk Reduction in Adults with Known Heart Disease and Overweight or Obesity,” March 11. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsggo&AN=edsgcl.787023005&authtype=sso&custid=ns315887.